Comparative Pharmacology
Head-to-head clinical analysis: FLONASE versus KENALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLONASE versus KENALOG.
FLONASE vs KENALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as cytokines, leukotrienes, and prostaglandins, thereby reducing nasal inflammation.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
2 sprays (50 mcg/spray) per nostril once daily; may increase to 2 sprays per nostril twice daily if needed. Intranasal route.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2-4 hours). This short half-life supports twice-daily dosing for systemic effects; however, intranasal administration achieves local therapeutic concentrations with minimal systemic exposure.
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Primarily hepatic metabolism (CYP3A4), with metabolites excreted in feces (approximately 87-90%) and urine (<5% unchanged). Less than 5% of a dose is excreted renally as unchanged drug.
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Category C
Category C
Corticosteroid
Corticosteroid